Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2013 1
2014 7
2015 5
2016 6
2017 4
2018 10
2019 8
2020 15
2021 19
2022 13
2023 10
2024 4

Text availability

Article attribute

Article type

Publication date

Search Results

93 results

Results by year

Citations

5 articles found by citation matching
Show all

Search results

Filters applied: . Clear all
Page 1
COVID-19 and Lung Cancer: A Comprehensive Overview from Outbreak to Recovery.
Bungaro M, Passiglia F, Scagliotti GV. Bungaro M, et al. Among authors: passiglia f. Biomedicines. 2022 Mar 26;10(4):776. doi: 10.3390/biomedicines10040776. Biomedicines. 2022. PMID: 35453526 Free PMC article. Review.
Lung cancer patients have been associated with an increased risk of COVID-19 infection, pulmonary complications, and worse survival outcomes compared to the general population. The world's leading professional organizations provided new recommendations for the diagn …
Lung cancer patients have been associated with an increased risk of COVID-19 infection, pulmonary complications, and worse sur …
Vaccine and immune cell therapy in non-small cell lung cancer.
Oliveres H, Caglevic C, Passiglia F, Taverna S, Smits E, Rolfo C. Oliveres H, et al. Among authors: passiglia f. J Thorac Dis. 2018 May;10(Suppl 13):S1602-S1614. doi: 10.21037/jtd.2018.05.134. J Thorac Dis. 2018. PMID: 29951309 Free PMC article. Review.
Despite new advances in therapeutics, lung cancer remains the first cause of mortality among different types of malignancies. ...Immunotherapy is based on the capability of the immune system to differentiate cancer cells from normal cells to fight against the …
Despite new advances in therapeutics, lung cancer remains the first cause of mortality among different types of malignancies. …
Immunotherapy in non-small-cell lung cancer: a bridge between research and clinical practice.
Passiglia F, Commendatore O, Vitali M, Conca R. Passiglia F, et al. Future Oncol. 2018 Jun;14(13s):41-60. doi: 10.2217/fon-2018-0098. Future Oncol. 2018. PMID: 29989452 Review.
Lung cancer has been historically considered a poorly immunogenic disease because of the few evidence of immune responses in affected patients and the limited efficacy of immunomodulating strategies. Recent understanding of the molecular mechanisms leading to can …
Lung cancer has been historically considered a poorly immunogenic disease because of the few evidence of immune responses in a …
Lung Cancer in Italy.
Passiglia F, Calandri M, Guerrera F, Malapelle U, Mangone L, Ramella S, Trisolini R, Novello S. Passiglia F, et al. J Thorac Oncol. 2019 Dec;14(12):2046-2052. doi: 10.1016/j.jtho.2019.05.019. J Thorac Oncol. 2019. PMID: 31757374 Free article. No abstract available.
Current treatment and future challenges in ROS1- and ALK-rearranged advanced non-small cell lung cancer.
Remon J, Pignataro D, Novello S, Passiglia F. Remon J, et al. Among authors: passiglia f. Cancer Treat Rev. 2021 Apr;95:102178. doi: 10.1016/j.ctrv.2021.102178. Epub 2021 Mar 10. Cancer Treat Rev. 2021. PMID: 33743408 Review.
Nonsmall cell lung cancer (NSCLC) presents different druggable genetic abnormalities, including ROS1 and ALK rearrangements, which share relevant clinical features and therapeutic strategies. ...
Nonsmall cell lung cancer (NSCLC) presents different druggable genetic abnormalities, including ROS1 and ALK rearrangements, w …
Second-Line Treatment of Non-Small Cell Lung Cancer: Clinical, Pathological, and Molecular Aspects of Nintedanib.
Corrales L, Nogueira A, Passiglia F, Listi A, Caglevic C, Giallombardo M, Raez L, Santos E, Rolfo C. Corrales L, et al. Among authors: passiglia f. Front Med (Lausanne). 2017 Feb 28;4:13. doi: 10.3389/fmed.2017.00013. eCollection 2017. Front Med (Lausanne). 2017. PMID: 28293555 Free PMC article. Review.
Lung carcinoma is the leading cause of death by cancer in the world. ...In recent years, evidence on the role of antiangiogenic agents have been established as important and effective therapeutic targets in non-small cell lung cancer (NSCLC). Nintedani …
Lung carcinoma is the leading cause of death by cancer in the world. ...In recent years, evidence on the role of antiangiogeni …
RAS as a positive predictive biomarker: focus on lung and colorectal cancer patients.
Malapelle U, Passiglia F, Cremolini C, Reale ML, Pepe F, Pisapia P, Avallone A, Cortinovis D, De Stefano A, Fassan M, Fontanini G, Galetta D, Lauricella C, Listì A, Loupakis F, Pagni F, Pietrantonio F, Pilotto S, Righi L, Bianchi AS, Parra HS, Tiseo M, Verzè M, Troncone G, Novello S. Malapelle U, et al. Among authors: passiglia f. Eur J Cancer. 2021 Mar;146:74-83. doi: 10.1016/j.ejca.2021.01.015. Epub 2021 Feb 12. Eur J Cancer. 2021. PMID: 33588147 Review.
In the last years, careful attention has been paid on KRAS and NRAS gene mutations in non-small-cell lung cancer (NSCLC) and colorectal cancer (CRC) patients because of their prognostic and predictive roles. ...
In the last years, careful attention has been paid on KRAS and NRAS gene mutations in non-small-cell lung cancer (NSCLC) and c …
RET-MAP: An International Multicenter Study on Clinicobiologic Features and Treatment Response in Patients With Lung Cancer Harboring a RET Fusion.
Aldea M, Marinello A, Duruisseaux M, Zrafi W, Conci N, Massa G, Metro G, Monnet I, Gomez Iranzo P, Tabbo F, Bria E, Guisier F, Vasseur D, Lindsay CR, Ponce-Aix S, Cousin S, Citarella F, Fallet V, Minatta JN, Eisert A, de Saint Basile H, Audigier-Valette C, Mezquita L, Calles A, Mountzios G, Tagliamento M, Remon Masip J, Raimbourg J, Terrisse S, Russo A, Cortinovis D, Rochigneux P, Pinato DJ, Cortellini A, Leonce C, Gazzah A, Ghigna MR, Ferrara R, Dall'Olio FG, Passiglia F, Ludovini V, Barlesi F, Felip E, Planchard D, Besse B. Aldea M, et al. Among authors: passiglia f. J Thorac Oncol. 2023 May;18(5):576-586. doi: 10.1016/j.jtho.2022.12.018. Epub 2023 Jan 13. J Thorac Oncol. 2023. PMID: 36646211 Free article.
METHODS: This retrospective multicenter study included patients with any-stage RET positive (RET+) NSCLC from 31 cancer centers. Molecular profiling included DNA/RNA sequencing or fluorescence in situ hybridization analyses. ...Median tumor mutational burden was 2.5 (range …
METHODS: This retrospective multicenter study included patients with any-stage RET positive (RET+) NSCLC from 31 cancer centers. Mole …
Benefits and Harms of Lung Cancer Screening by Chest Computed Tomography: A Systematic Review and Meta-Analysis.
Passiglia F, Cinquini M, Bertolaccini L, Del Re M, Facchinetti F, Ferrara R, Franchina T, Larici AR, Malapelle U, Menis J, Passaro A, Pilotto S, Ramella S, Rossi G, Trisolini R, Novello S. Passiglia F, et al. J Clin Oncol. 2021 Aug 10;39(23):2574-2585. doi: 10.1200/JCO.20.02574. Epub 2021 Jun 2. J Clin Oncol. 2021. PMID: 34236916
The analysis of lung cancer-related mortality by sex revealed nonsignificant differences between men and women (P = .21; I-squared = 33.6%). CONCLUSION: Despite there still being uncertainty about overdiagnosis estimate, this meta-analysis suggested that the CTLS be …
The analysis of lung cancer-related mortality by sex revealed nonsignificant differences between men and women (P = .21; I-squ …
KRAS inhibition in non-small cell lung cancer: Past failures, new findings and upcoming challenges.
Passiglia F, Malapelle U, Del Re M, Righi L, Pagni F, Furlan D, Danesi R, Troncone G, Novello S. Passiglia F, et al. Eur J Cancer. 2020 Sep;137:57-68. doi: 10.1016/j.ejca.2020.06.023. Epub 2020 Jul 31. Eur J Cancer. 2020. PMID: 32745965 Review.
Despite the high prevalence of Kirsten rat sarcoma (KRAS) mutations in non-small cell lung cancer (NSCLC), for a long time it has been defined as an 'undruggable target', with precision medicine not considered as an adequate approach to treat this subgroup of patien …
Despite the high prevalence of Kirsten rat sarcoma (KRAS) mutations in non-small cell lung cancer (NSCLC), for a long time it …
93 results